

Piera Capranzano

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1645741/piera-capranzano-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

178
papers

4,665
citations

37
h-index

63
g-index

212
ext. papers

5,561
ext. citations

4.3
avg, IF

5.17
L-index

#	Paper	IF	Citations
178	Calcification and Coronary Interventions 2022 , 119-138		
177	Sex Differences in Outcomes After Percutaneous Coronary Intervention or Coronary Artery Bypass Graft for Left Main Disease: From the DELTA Registries.. <i>Journal of the American Heart Association</i> , 2022 , e022320	6	1
176	Parenteral Anticoagulant Agents in PCI 2022 , 439-445		
175	Basics of Antiplatelet and Anticoagulant Therapy for Cardiovascular Disease 2022 , 407-419		
174	Effect of post-procedural evidence-based therapy on 2-year prognosis after transcatheter mitral valve repair. <i>European Journal of Heart Failure</i> , 2021 , 23, 677-679	12.3	1
173	Antithrombotic Management of Elderly Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 723-738	5	5
172	Tackling the gap in platelet inhibition with oral antiplatelet agents in high-risk patients undergoing percutaneous coronary intervention. <i>Expert Review of Cardiovascular Therapy</i> , 2021 , 19, 519-535	2.5	3
171	Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021 , 98, E908-E917	2.7	2
170	Impact of diabetes mellitus on female subjects undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI international registry. <i>International Journal of Cardiology</i> , 2021 , 322, 65-69	3.2	0
169	Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021 , 97, E704-E715	2.7	3
168	Suitability for elderly with heart disease of a QR code-based feedback of drug intake: Overcoming limitations of current medication adherence telemonitoring systems. <i>International Journal of Cardiology</i> , 2021 , 327, 209-216	3.2	4
167	Prevalence, predictors, and outcomes of patient prosthesis mismatch in women undergoing TAVI for severe aortic stenosis: Insights from the WIN-TAVI registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021 , 97, 516-526	2.7	5
166	Impact of direct oral anticoagulants on evolution of post-thrombotic syndrome. <i>Thrombosis Research</i> , 2021 , 207, 10-15	8.2	
165	The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement: Analysis from the Women's International Transcatheter Aortic Valve Implantation (WIN-TAVI) registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020 , 96, 198-207	2.7	4
164	Edwards SAPIEN Versus Medtronic Aortic Bioprosthesis in Women Undergoing Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). <i>American Journal of Cardiology</i> , 2020 , 125, 441-448	2.48	4
163	Timing of cardioversion in atrial fibrillation: the sooner the better?. <i>European Heart Journal Supplements</i> , 2020 , 22, L41-L43	1.5	
162	Antithrombotic pharmacotherapy after transcatheter aortic valve implantation: an update. <i>Expert Review of Cardiovascular Therapy</i> , 2019 , 17, 479-496	2.5	2

161	Switching between P2Y inhibitors: Rationale, methods, and expected consequences. <i>Vascular Pharmacology</i> , 2019 , 116, 4-7	5.9	2
160	Predictors of long-term adverse events after Absorb bioresorbable vascular scaffold implantation: a 1,933-patient pooled analysis from international registries. <i>EuroIntervention</i> , 2019 , 15, 623-630	3.1	9
159	De-escalation of oral P2Y12 inhibitors guided by platelet function testing in ACS patients undergoing PCI: impact of diabetes mellitus. <i>EuroIntervention</i> , 2019 , 15, e486-e489	3.1	
158	The sunset of triple antithrombotic therapy for atrial fibrillation patients. <i>European Heart Journal Supplements</i> , 2019 , 21, B36-B37	1.5	
157	Pharmacodynamics During Transition Between Platelet P2Y Inhibiting Therapies. <i>Interventional Cardiology Clinics</i> , 2019 , 8, 321-340	1.4	2
156	Impact of Discharge Location After Transcatheter Aortic Valve Replacement on 1-Year Outcomes in Women: Results From the WIN-TAVI Registry. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 199-207	3.8	4
155	Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: From the WIN-TAVI registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019 , 93, 1124-1131	2.7	8
154	European Society of Cardiology, acute cardiovascular care association, SCAD study group: a position paper on spontaneous coronary artery dissection. <i>European Heart Journal</i> , 2018 , 39, 3353-3368	9.5	237
153	Feasibility and Outcomes of Repeat Percutaneous Edge-to-Edge Mitral Valve Repair Procedures in Patients at High Risk for Surgery. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 818-820	5	0
152	TAVI Postprocedural Management 2018 , 483-499		
151	Incidence, Timing, Causes and Predictors of Early and Late Re-Hospitalization in Patients Who Underwent Percutaneous Mitral Valve Repair With the MitraClip System. <i>American Journal of Cardiology</i> , 2018 , 121, 1253-1259	3	11
150	Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization. <i>Circulation</i> , 2018 , 137, 2435-2445	16.7	72
149	Early and Mid-Term Outcomes of Transcatheter Aortic Valve Replacement Using the New Generation Self-Expanding Corevalve Evolut R Device. <i>Structural Heart</i> , 2018 , 2, 229-234	0.6	1
148	1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement: Results From the First WIN-TAVI Registry. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 1-12	5	40
147	Decision Analytic Markov Model Weighting Expected Benefits and Current Limitations of First-Generation Bioresorbable Vascular Scaffolds: Implications for Manufacturers and Next Device Iterations. <i>Circulation: Cardiovascular Interventions</i> , 2018 , 11, e005768	6	4
146	Percutaneous coronary and structural interventions in women: a position statement from the EAPCI Women Committee. <i>EuroIntervention</i> , 2018 , 14, e1227-e1235	3.1	7
145	Appraisal of key trials in aortic and mitral fields. <i>EuroIntervention</i> , 2018 , 14, AB19-AB32	3.1	
144	Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the European Multicentre GHOST-EU Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2018 , 91, 444-453	2.7	6

143	Vascular response and healing profile of everolimus-eluting bioresorbable vascular scaffolds for percutaneous treatment of chronic total coronary occlusions: A one-year optical coherence tomography analysis from the GHOST-CTO registry. <i>International Journal of Cardiology</i> , 2018 , 253, 45-49	3.2	5
142	Pharmacokinetics of new oral anticoagulants: implications for use in routine care. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 1057-1069	5.5	21
141	Lipid Plaque Modification During Resorption of Absorb Bioresorbable Scaffold: Insights From Optical Coherence Tomography. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 2123-2124	5	2
140	Incidence of Long-Term Structural Valve Dysfunction and Bioprosthetic Valve Failure After Transcatheter Aortic Valve Replacement. <i>Journal of the American Heart Association</i> , 2018 , 7, e008440	6	56
139	Impact of Baseline Atrial Fibrillation on Outcomes Among Women Who Underwent Contemporary Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). <i>American Journal of Cardiology</i> , 2018 , 122, 1909-1916	3	11
138	Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 560-568	5	13
137	A Risk Model for Prediction of 1-Year Mortality in Patients Undergoing MitraClip Implantation. <i>American Journal of Cardiology</i> , 2017 , 119, 1443-1449	3	16
136	Feasibility and predictors of early discharge after percutaneous edge-to-edge mitral valve repair. <i>Heart</i> , 2017 , 103, 931-936	5.1	6
135	Strategies and Outcomes of Repeat Mitral Valve Interventions after Failed MitraClip Therapy. <i>Cardiology</i> , 2017 , 137, 114-120	1.6	5
134	Bioresorbable Vascular Scaffolds as a Treatment Option for Left Main Lesions. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 743-745	5	1
133	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: A systematic review and network meta-analysis. <i>International Journal of Cardiology</i> , 2017 , 231, 162-169	3.2	54
132	Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. <i>New England Journal of Medicine</i> , 2017 , 377, 1791-2	59.2	5
131	Patients with non-ST segment elevation acute coronary syndromes managed without coronary revascularization: A population needing treatment improvement. <i>International Journal of Cardiology</i> , 2017 , 245, 35-42	3.2	3
130	Optimized Screening of Coronary Artery Disease With Invasive Coronary Angiography and Ad Hoc Percutaneous Coronary Intervention During Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2017 , 10,	6	18
129	Clinical Outcomes Following Intravascular Imaging-Guided Versus Coronary Angiography-Guided Percutaneous Coronary Intervention With Stent Implantation: A Systematic Review and Bayesian Network Meta-Analysis of 11 Studies and 17,882 Patients. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 2488-2498	5	111
128	Interventional Treatment of Acute Coronary Syndrome (ACS): Non-ST Elevation ACS (NSTEMI-ACS) 2017 , 51-59		
127	Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOST-EU registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017 , 89, 812-818	2.7	12
126	Bioresorbable vascular scaffold use for coronary bifurcation lesions: A substudy from GHOST EU registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017 , 89, 47-56	2.7	18

125	Procedural Management of Patients With Advanced Heart Failure Undergoing MitraClip Implantation (From the GRASP Registry). <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2017 , 31, e6-e8	2.1	9
124	Twelve-month outcomes after bioresorbable vascular scaffold implantation in patients with acute coronary syndromes. Data from the European Multicenter GHOST-EU Extended Registry. <i>EuroIntervention</i> , 2017 , 13, e1104-e1111	3.1	9
123	Current status of transcatheter mitral valve therapy in Europe: results from an EAPCI survey (Part II). <i>EuroIntervention</i> , 2017 , 12, 1934-1939	3.1	10
122	Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score. <i>EuroIntervention</i> , 2017 , 12, 2110-2117	3.1	92
121	Late Self-Apposition With One-Year Persisting Uncoverage of Malapposed Bioresorbable Polymeric Struts. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 951.e5-951.e6	3.8	
120	Left main interventions with BRSs 2017 , 326-331		
119	Transcatheter Aortic-Valve Replacement. <i>New England Journal of Medicine</i> , 2016 , 375, 700-1	59.2	12
118	MitraClip Implantation for the Treatment of New-Onset Systolic Anterior Motion of the Mitral Valve After Transcatheter Aortic Valve Replacement. <i>Annals of Thoracic Surgery</i> , 2016 , 102, e517-e519	2.7	6
117	Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization: A Post Hoc Analysis of the DELTA Registry. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 2280-2288	5	17
116	Risk stratification after ST-segment elevation myocardial infarction. <i>Expert Review of Cardiovascular Therapy</i> , 2016 , 14, 1349-1360	2.5	5
115	Update on clinical evidence (Part II): A summary of the main post market studies. <i>Catheterization and Cardiovascular Interventions</i> , 2016 , 88, 31-37	2.7	
114	Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016 , 5, 475-86	4.3	12
113	Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Review of the literature and practical considerations. <i>American Heart Journal</i> , 2016 , 176, 44-52	4.9	17
112	1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 440-9	5	17
111	Embolization of Fractured Bioresorbable Scaffold Struts: Insights From 2- and 3-Dimensional Optical Coherence Tomography. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, e37-e38	5	2
110	Usefulness of 3D OCT to Diagnose a Noncircumferential Open-Cell Stent Fracture. <i>JACC: Cardiovascular Imaging</i> , 2016 , 9, 210-1	8.4	4
109	Impact of chronic kidney disease on outcomes after percutaneous mitral valve repair with the MitraClip system: insights from the GRASP registry. <i>EuroIntervention</i> , 2016 , 11, e1649-57	3.1	21
108	One-year outcomes after Absorb bioresorbable vascular scaffold implantation in routine clinical practice. <i>EuroIntervention</i> , 2016 , 12, e152-9	3.1	6

107	Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. <i>EuroIntervention</i> , 2016 , 12, e623-31	3.1	12
106	Motivations for and barriers to choosing an interventional cardiology career path: results from the EAPCI Women Committee worldwide survey. <i>EuroIntervention</i> , 2016 , 12, 53-9	3.1	27
105	Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry. <i>EuroIntervention</i> , 2016 , 12, e550-6	3.1	23
104	Current status of transcatheter valve therapy in Europe: results from an EAPCI survey. <i>EuroIntervention</i> , 2016 , 12, 890-5	3.1	43
103	Early results of MitraClip system implantation by real-time three-dimensional speckle-tracking left ventricle analysis. <i>Journal of Cardiovascular Medicine</i> , 2016 , 17, 843-9	1.9	7
102	Everolimus-eluting bioresorbable vascular scaffolds versus second generation drug-eluting stents for percutaneous treatment of chronic total coronary occlusions: Technical and procedural outcomes from the GHOST-CTO registry. <i>Catheterization and Cardiovascular Interventions</i> , 2016 , 88, E155-E163	2.7	10
101	Basics of Antiplatelet and Anticoagulant Therapy for Cardiovascular Disease 2016 , 377-388		
100	Parenteral Anticoagulant Agents in PCI 2016 , 408-414		
99	Parenteral Antiplatelet Agents in PCI 2016 , 415-420		
98	Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement: A Systematic Review and Meta-analysis. <i>Annals of Internal Medicine</i> , 2016 , 165, 334-44	8	84
97	Transfemoral transcatheter aortic-valve replacement should be preferred over surgery in most intermediate-risk patients. <i>Evidence-Based Medicine</i> , 2016 , 21, 173		
96	Is the Metallic Stent a Safe Treatment for Bioresorbable Scaffold Failure?: Insights From Optical Coherence Tomography. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 976-7	5	
95	Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016 , 5, 253-62	4.3	43
94	New-onset atrial fibrillation and increased mortality after transcatheter aortic valve implantation: A causal or spurious association?. <i>International Journal of Cardiology</i> , 2016 , 203, 264-6	3.2	18
93	Percutaneous mitral valve repair with the MitraClip system in the elderly: One-year outcomes from the GRASP registry. <i>International Journal of Cardiology</i> , 2016 , 224, 440-446	3.2	13
92	Management issues of chronic therapy with non-vitamin K oral anticoagulants or antiplatelet agents: Different or alike?. <i>International Journal of Cardiology</i> , 2016 , 221, 695-6	3.2	2
91	Acute and 30-Day Outcomes in Women After TAVR: Results From the WIN-TAVI (Women International Transcatheter Aortic Valve Implantation) Real-World Registry. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1589-600	5	56
90	Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8,	6	125

89	Cyphering the mechanism of late failure of bioresorbable vascular scaffolds in percutaneous coronary intervention of the left main coronary artery. <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, e95-e97	5.7	1
88	Early discharge after transfemoral transcatheter aortic valve implantation. <i>Heart</i> , 2015 , 101, 1485-90	5.1	66
87	One-Year Coverage by Optical Coherence Tomography of a Bioresorbable Scaffold Neocarina: Is It Safe to Discontinue Dual-Antiplatelet Therapy?. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 1205.e5-6	3.8	
86	Impact of moderate preoperative chronic kidney disease on mortality after transcatheter aortic valve implantation. <i>International Journal of Cardiology</i> , 2015 , 189, 77-8	3.2	3
85	Longitudinal elongation, axial compression, and effects on strut geometry of bioresorbable vascular scaffolds: insights from 2- and 3-dimensional optical coherence tomography imaging. <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, e35-e37	5	3
84	Meta-Analyses of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation: Do Bleeding and Stent Thrombosis Weigh Similar on Mortality?. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1639-1640	15.1	24
83	Acute Kidney Injury With the RenalGuard System in Patients Undergoing Transcatheter Aortic Valve Replacement: The PROTECT-TAVI Trial (PROphylactic effect of furosemide-induced diuresis with matched isotonic intravenous hydration in Transcatheter Aortic Valve Implantation). <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 1595-604	5	80
82	Risk stratification for secondary prevention with ticagrelor and aspirin: A closer look to patient subsets from the PEGASUS-TIMI 54 trial. <i>International Journal of Cardiology</i> , 2015 , 201, 276-8	3.2	3
81	Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. <i>BMJ, The</i> , 2015 , 351, h5392	5.9	77
80	Gender-related clinical and echocardiographic outcomes at 30-day and 12-month follow up after MitraClip implantation in the GRASP registry. <i>Catheterization and Cardiovascular Interventions</i> , 2015 , 85, 889-97	2.7	30
79	Anatomical features and management of bioresorbable vascular scaffolds failure: A case series from the GHOST registry. <i>Catheterization and Cardiovascular Interventions</i> , 2015 , 85, 1150-61	2.7	27
78	New insights on acute expansion and longitudinal elongation of bioresorbable vascular scaffolds in vivo and at bench test: a note of caution on reliance to compliance charts and nominal length. <i>Catheterization and Cardiovascular Interventions</i> , 2015 , 85, E99-E107	2.7	6
77	Extended use of percutaneous edge-to-edge mitral valve repair beyond EVEREST (Endovascular Valve Edge-to-Edge Repair) criteria: 30-day and 12-month clinical and echocardiographic outcomes from the GRASP (Getting Reduction of Mitral Insufficiency by Percutaneous Clip Implantation) registry. <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 74-82	5	82
76	Moderate and severe preoperative chronic kidney disease worsen clinical outcomes after transcatheter aortic valve implantation: meta-analysis of 4992 patients. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8, e002220	6	49
75	Impact of postoperative acute kidney injury on clinical outcomes after transcatheter aortic valve implantation: A meta-analysis of 5,971 patients. <i>Catheterization and Cardiovascular Interventions</i> , 2015 , 86, 518-27	2.7	61
74	Comparison of suture-based vascular closure devices in transfemoral transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2015 , 11, 690-7	3.1	37
73	Bioresorbable vascular scaffolds in left main coronary artery disease. <i>EuroIntervention</i> , 2015 , 11 Suppl V, V135-8	3.1	4
72	Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. <i>EuroIntervention</i> , 2015 , 10, 1144-53	3.1	340

71	Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. <i>EuroIntervention</i> , 2015 , 11, 45-52	3.1	111
70	Comparison of percutaneous coronary intervention (with drug-eluting stents) versus coronary artery bypass grafting in women with severe narrowing of the left main coronary artery (from the Women-Drug-Eluting stent for Left main coronary Artery disease Registry). <i>American Journal of Cardiology</i> , 2014 , 113, 1348-55	3	11
69	Early cardiovascular remodelling in Fabry disease. <i>Journal of Inherited Metabolic Disease</i> , 2014 , 37, 109-116	1.4	10
68	Acute left atrial spontaneous echocardiographic contrast and suspicious thrombus formation following mitral regurgitation reduction with the MitraClip system. <i>JACC: Cardiovascular Interventions</i> , 2014 , 7, 1322-3	5	8
67	A simple risk tool (the OBSERVANT score) for prediction of 30-day mortality after transcatheter aortic valve replacement. <i>American Journal of Cardiology</i> , 2014 , 113, 1851-8	3	103
66	Percutaneous mitral valve repair with the MitraClip system for severe mitral regurgitation in patients with surgical mitral valve repair failure. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 836-8	15.1	26
65	Meta-analysis of randomized controlled trials of preprocedural statin administration for reducing contrast-induced acute kidney injury in patients undergoing coronary catheterization. <i>American Journal of Cardiology</i> , 2014 , 114, 541-8	3	37
64	ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome. <i>European Heart Journal Supplements</i> , 2014 , 16, C2-C28	1.5	2
63	Association of tricuspid regurgitation with clinical and echocardiographic outcomes after percutaneous mitral valve repair with the MitraClip System: 30-day and 12-month follow-up from the GRASP Registry. <i>European Heart Journal Cardiovascular Imaging</i> , 2014 , 15, 1246-55	4.1	91
62	Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes. <i>Expert Review of Cardiovascular Therapy</i> , 2014 , 12, 1185-203	2.5	19
61	Long-term outcomes of percutaneous coronary interventions or coronary artery bypass grafting for left main coronary artery disease in octogenarians (from a Drug-Eluting stent for Left main Artery registry substudy). <i>American Journal of Cardiology</i> , 2014 , 113, 2007-12	3	23
60	Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for ostial/midshaft lesions in unprotected left main coronary artery from the DELTA registry: a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main coronary artery disease. <i>JACC: Cardiovascular Interventions</i> , 2014 , 7, 251-61	5	38
59	CABG versus PCI in diabetic patients with multivessel disease after risk stratification by the SYNTAX score: a pooled analysis of the SYNTAX and FREEDOM trials. <i>International Journal of Cardiology</i> , 2014 , 173, 548-9	3.2	4
58	Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. <i>Catheterization and Cardiovascular Interventions</i> , 2013 , 81, 42-9	2.7	12
57	Meta-analysis of everolimus-eluting stents versus first-generation drug-eluting stents in patients with left main coronary artery undergoing percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2013 , 168, 1718-9	3.2	5
56	Basics of Antithrombotic Therapy for Cardiovascular Disease: Pharmacologic Targets of Platelet Inhibitors and Anticoagulants. <i>Interventional Cardiology Clinics</i> , 2013 , 2, 499-513	1.4	1
55	Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.	5	61
54	Personalizing oral anticoagulant treatment in patients with atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2013 , 11, 959-73	2.5	10

53	Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation. <i>Journal of Thrombosis and Thrombolysis</i> , 2013 , 35, 155-64	5.1	21
52	Initial experience of percutaneous coronary intervention in bifurcations with bioresorbable vascular scaffolds using different techniques--insights from optical coherence tomography. <i>International Journal of Cardiology</i> , 2013 , 170, e33-5	3.2	3
51	Combination Antithrombotic Management of STEMI with Pharmacoinvasive Strategy, Primary PCI, or Rescue PCI. <i>Interventional Cardiology Clinics</i> , 2013 , 2, 573-583	1.4	
50	AuthorsReply. <i>Journal of the American Society of Echocardiography</i> , 2013 , 26, 219-20	5.8	
49	Percutaneous recanalization of chronic total occlusions: wherein lies the body of proof?. <i>American Heart Journal</i> , 2013 , 165, 133-42	4.9	20
48	Dual antiplatelet therapy in patients with diabetes mellitus: special considerations. <i>Expert Review of Cardiovascular Therapy</i> , 2013 , 11, 307-17	2.5	6
47	Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients. <i>International Journal of Cardiology</i> , 2013 , 167, 1237-41	3.2	68
46	Emergency management of ST-elevation myocardial infarction 2013 , 80-96		
45	Objectifying the impact of incomplete revascularization by repeat angiographic risk assessment with the residual SYNTAX score after left main coronary artery percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2013 , 82, 333-40	2.7	28
44	Coronary artery bypass graft versus percutaneous coronary intervention with drug-eluting stent implantation for diabetic patients with unprotected left main coronary artery disease: the D-DELTA registry. <i>EuroIntervention</i> , 2013 , 9, 803-8	3.1	2
43	Percutaneous mitral valve repair in patients with prior cardiac surgery. <i>Journal of Cardiac Surgery</i> , 2012 , 27, 295-8	1.3	6
42	Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012 , 65, 105-106	0.7	1
41	Left cardiac chambers reverse remodeling after percutaneous mitral valve repair with the MitraClip system. <i>Journal of the American Society of Echocardiography</i> , 2012 , 25, 1099-105	5.8	39
40	Bivalirudin for primary percutaneous coronary intervention in acute myocardial infarction: the HORIZONS-AMI trial. <i>Expert Review of Cardiovascular Therapy</i> , 2012 , 10, 411-22	2.5	7
39	Impact of adjunctive cilostazol therapy versus high maintenance dose of clopidogrel in suboptimal responders with diabetes mellitus. <i>Revista Espanola De Cardiologia</i> , 2012 , 65, 105-6	1.5	9
38	Increasing CHADS ₂ scores may attenuate the benefit of novel oral anticoagulants versus warfarin in reducing intracranial bleeding. <i>International Journal of Cardiology</i> , 2012 , 161, 176-7	3.2	4
37	Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. <i>JACC: Cardiovascular Interventions</i> , 2012 , 5, 293-300	5	38
36	Drug-eluting stent for left main coronary artery disease. The DELTA registry: a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. <i>JACC: Cardiovascular Interventions</i> , 2012 , 5, 718-27	5	102

35	Comparative one-year effectiveness of percutaneous coronary intervention versus coronary artery bypass grafting in patients. <i>American Journal of Cardiology</i> , 2012 , 110, 1452-8	3	10
34	Late stent thrombosis: the last remaining obstacle in coronary interventional therapy. <i>Current Cardiology Reports</i> , 2012 , 14, 408-17	4.2	12
33	Safety and effectiveness of the Catania Polyzene-F coated stent in real world clinical practice: 12-month results from the ATLANTA 2 registry. <i>EuroIntervention</i> , 2012 , 7, 1062-8	3.1	7
32	Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 30-9	15.1	44
31	A post-hoc analysis of the CUSTOMIZE Registry on the differential impact of EuroSCORE and SYNTAX score in left main patients with intermediate Global Risk. <i>International Journal of Cardiology</i> , 2011 , 150, 116-7	3.2	3
30	Functional profile of the platelet P2Y ₁₂ receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2011 , 105, 730-2	7	34
29	Platelet function profiles in the elderly: results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 1149-57	7	26
28	Haemostatic profiles assessed by thromboelastography in patients with end-stage renal disease. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 67-74	7	33
27	Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 253-62	7	32
26	Impact of diabetes mellitus on long-term follow-up of percutaneous coronary intervention based on clinical presentation of coronary artery disease. <i>Journal of Cardiovascular Medicine</i> , 2011 , 12, 405-10	1.9	8
25	Functional and clinical implications of cardiac resynchronization therapy on outcomes of diabetic patients with heart failure. <i>Journal of Cardiovascular Medicine</i> , 2011 , 12, 396-400	1.9	4
24	Comparison of one-year outcomes of percutaneous coronary intervention versus coronary artery bypass grafting in patients with unprotected left main coronary artery disease and acute coronary syndromes (from the CUSTOMIZE Registry). <i>American Journal of Cardiology</i> , 2011 , 108, 355-9	3	35
23	Global risk classification and clinical SYNTAX (synergy between percutaneous coronary intervention with TAXUS and cardiac surgery) score in patients undergoing percutaneous or surgical left main revascularization. <i>JACC: Cardiovascular Interventions</i> , 2011 , 4, 287-97	5	100
22	Validating the EXCEL hypothesis: a propensity score matched 3-year comparison of percutaneous coronary intervention versus coronary artery bypass graft in left main patients with SYNTAX score B2. <i>Catheterization and Cardiovascular Interventions</i> , 2011 , 77, 936-43	2.7	20
21	Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. <i>Circulation: Cardiovascular Interventions</i> , 2011 , 4, 180-7	6	151
20	Clinical impact of enhanced inhibition of P2Y ₁₂ -mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. <i>Hospital Practice (1995)</i> , 2010 , 38, 38-43	2.2	2
19	EuroSCORE refines the predictive ability of SYNTAX score in patients undergoing left main percutaneous coronary intervention. <i>American Heart Journal</i> , 2010 , 159, 103-9	4.9	98
18	Long-term outcomes after drug-eluting stent for the treatment of ostial left anterior descending coronary artery lesions. <i>American Heart Journal</i> , 2010 , 160, 973-8	4.9	13

17	Sirolimus versus paclitaxel-eluting stents in small coronary vessels: long-term outcomes from a single-center registry. <i>Journal of Cardiovascular Medicine</i> , 2010 , 11, 365-8	1.9	6
16	Plaque distribution patterns in distal left main coronary artery to predict outcomes after stent implantation. <i>JACC: Cardiovascular Interventions</i> , 2010 , 3, 624-31	5	25
15	Clinical development of selective anticoagulants: a state of the art. <i>Reviews on Recent Clinical Trials</i> , 2010 , 5, 85-93	1.2	3
14	Real world safety and efficacy of the Janus Tacrolimus-Eluting stent: long-term clinical outcome and angiographic findings from the Tacrolimus-Eluting STent (TEST) registry. <i>Catheterization and Cardiovascular Interventions</i> , 2009 , 73, 243-8	2.7	18
13	Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists. <i>Catheterization and Cardiovascular Interventions</i> , 2009 , 73, 1-14	2.7	28
12	Long-term clinical outcomes after drug-eluting stent implantation in unprotected left main coronary artery disease. <i>Catheterization and Cardiovascular Interventions</i> , 2009 , 73, 291-8	2.7	19
11	A novel approach to define risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents: the DERIVATION score. <i>Clinical Research in Cardiology</i> , 2009 , 98, 240-8	6.1	12
10	Usefulness of SYNTAX score to select patients with left main coronary artery disease to be treated with coronary artery bypass graft. <i>JACC: Cardiovascular Interventions</i> , 2009 , 2, 731-8	5	118
9	Impact of P2Y ₁₂ inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients. <i>Thrombosis Research</i> , 2009 , 124, 318-22	8.2	33
8	Pharmacogenetics in cardiovascular antithrombotic therapy. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 1041-57	15.1	81
7	Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. <i>Expert Review of Cardiovascular Therapy</i> , 2009 , 7, 361-9	2.5	11
6	Pharmacology of emerging novel platelet inhibitors. <i>American Heart Journal</i> , 2008 , 156, S10-5	4.9	74
5	A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. <i>European Heart Journal</i> , 2008 , 29, 2202-11	9.5	161
4	Prasugrel: a novel platelet ADP P2Y ₁₂ receptor antagonist. A review on its mechanism of action and clinical development. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 2893-900	4	31
3	Early discharge in acute myocardial infarction after clinical and angiographic risk assessment. <i>Journal of Cardiovascular Medicine</i> , 2008 , 9, 858-61	1.9	3
2	Sicilian DES Registry: prospective in-hospital and 9-month clinical and angiographic follow-up in selected high restenosis risk patients. <i>Journal of Cardiovascular Medicine</i> , 2008 , 9, 161-8	1.9	3
1	Complete versus incomplete revascularization in patients with multivessel disease undergoing percutaneous coronary intervention with drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2008 , 72, 448-56	2.7	52